Hyperparathyroid and hypoparathyroid disorders

New England Journal of Medicine

Volumn 343, Issue 25, 2000, Pages 1863-1875

  Marx, Stephen J ^a  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HORMONE ACTION; HUMAN; HYPERPARATHYROIDISM; HYPOPARATHYROIDISM; MULTIPLE ENDOCRINE NEOPLASIA; PARATHYROID HORMONE BLOOD LEVEL; PRIMARY HYPERPARATHYROIDISM; PRIORITY JOURNAL; PSEUDOHYPOPARATHYROIDISM; REVIEW; UREMIA;

ADENOMA; BONE DISEASES; CALCIUM; DISEASE PROGRESSION; HUMANS; HYPERCALCEMIA; HYPERPARATHYROIDISM; HYPOCALCEMIA; HYPOPARATHYROIDISM; INFANT, NEWBORN; KIDNEY FAILURE, CHRONIC; PARATHYROID GLANDS; PARATHYROID HORMONE; PARATHYROID NEOPLASMS; VITAMIN D;

EID: 0034700450     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM200012213432508     Document Type: Review

References (109)

1. Parathyroid hormone and parathyroid hormone-related peptide in the regulation of calcium homeostasis and bone development
2. G-protein-coupled, extracellular Ca2+-sensing receptor: A versatile regulator of diverse cellular functions
3. Novel GPCRs and their endogenous ligands: Expanding the boundaries of physiology and pharmacology
4. Sequences in the human parathyroid hormone gene that bind the 1,25-dihydroxyvitamin D3 receptor and mediate transcriptional repression in response to 1,25-dihydroxyvitamin D3
5. RNA-protein binding and post-transcriptional regulation of parathyroid hormone gene expression by calcium and phosphate
6. The interaction between Ku antigen and REF1 protein mediates negative gene regulation by extracellular calcium
7. Parathyroid cell proliferation in normal and chronic renal failure rats: The effects of calcium, phosphate, and vitamin D
8. Normalization of mineral ion homeostasis by dietary means prevents hyperparathyroidism, rickets, and osteomalacia, but not alopecia in vitamin D receptor-ablated mice
9. The vitamin D receptor and the syndrome of hereditary 1,25-dihydroxyvitamin D-resistant rickets
10. Interactions of parathyroid hormone and parathyroid homone-related protein with their receptors
11. Receptors for parathyroid hormone and parathyroid hormone-related peptide: Exploration of their biological importance
12. TIP39: A new neuropeptide and PTH2-receptor agonist from hypothalamus
13. The physiology of parathyroid hormone-related protein
14. Clinical performance of parathyroid hormone immunometric assays
15. Evaluation of a new, rapid and automated immunochemiluminometric assay for the measurement of serum intact parathyroid hormone
16. A non-(1-84) circulating parathyroid hormone (PTH) fragment interferes significantly with intact PTH commercial assay measurements in uremic samples
17. A novel immunoradiometric assay detects full-length human PTH but not amino-terminally truncated fragments: Implications for PTH measurements in renal failure
18. A prospective trial evaluating a standard approach to reoperation for missed parathyroid adenoma
19. Improved success rate in reoperative parathyroidectomy with intraoperative PTH assay
20. Molecular basis of primary hyperparathyroidism
21. Monoclonality of parathyroid tumors in chronic renal failure and in primary parathyroid hyperplasia
22. Menin interacts with the AP1 transcription factor JunD and represses JunD-activated transcription
23. Li-Fraumeni syndrome
24. The cyclins and cyclin-dependent kinase inhibitors in hormonal regulation of proliferation and differentiation
25. The Rb family of cell cycle regulatory factors: Clinical implications
26. Mutations in G proteins and G protein-coupled receptors in endocrine disease
27. Multiple endocrine neoplasias
28. Genomic localization of novel candidate tumor suppressor gene loci in human parathyroid adenomas
29. Alternative genetic pathways in parathyroid tumorigenesis
30. Lessons from hereditary colorectal cancer
31. Hereditary cancer: Two hits revisited
32. Loss of the retinoblastoma tumor-suppressor gene in parathyroid carcinoma
33. p53 Abnormalities in human parathyroid carcinoma
34. Comparative genome hybridization analysis of human parathyroid tumors
35. Somatic mutation of the MEN1 gene in parathyroid tumours
36. Mutational analysis of the extracellular Ca(2+)-sensing receptor gene in human parathyroid tumors
37. Vitamin D receptor as a candidate tumor-suppressor gene in severe hyperparathyroidism of uremia
38. Familial hypercalcemia and hypercalciuria caused by a novel mutation in the cytoplasmic tall of the calcium receptor
39. A novel cyclin encoded by a bell-linked candidate oncogene
40. Cyclin D1/PRAD1 expression in parathyroid adenomas: An immunohistochemical study
41. The extracellular calcium-sensing receptor: Its role in health and disease
42. The rise and fall of primary hyperparathyroidism: A population-based study in Rochester, Minnesota, 1965-1992
43. Population-based screening for primary hyperparathyroidism with serum calcium and parathyroid hormone values in menopausal women
44. Dose-response relationships for radiation-induced hyperparathyroidism
45. Hyperparathyroidism and long-term lithium therapy - A cross-sectional study and the effect of lithium withdrawal
46. Lithium induces abnormal calcium-regulated PTH release in dispersed bovine parathyroid cells
47. Familial isolated hyperparathyroidism maps to the hyperparathyroidism-jaw tumor locus in 1q21-q32 in a subset of families
48. Familial isolated hyperparathyroidism as a variant of multiple endocrine neoplasia type 1 in a large Danish pedigree
49. Multiple endocrine neoplasia type 1: Clinical and genetic topics
50. Contrasting paradigms for hereditary hyperfunction of endocrine cells
51. Risk and penetrance of primary hyperparathyroidism in multiple endocrine neoplasia type 2A families with mutations at codon 634 of the RET proto-oncogene
52. Hereditary hyperparathyroidism-jaw tumor syndrome: The endocrine tumor gene HRPT2 maps to chromosome 1q21-q31
53. Mapping the gene causing hereditary primary hyperparathyroidism in a Portuguese kindred to chromosome 1q22-q31
54. Clinical presentation of primary hyperparathyroidism
55. A 10-year prospective study of primary hyperparathyroidism with or without parathyroid surgery
56. Clinical manifestations of primary hyperparathyroidism before and after parathyroidectomy: A case-control study
57. Health status improvement after surgical correction of primary hyperparathyroidism in patients with high and low preoperative calcium levels
58. Cardiac abnormalities in patients with primary hyperparathyroidism: Implications for follow-up
59. Survival after diagnosis of hyperparathyroidism: A population-based study
60. Parathyroid hormone exerts disparate effects on osteoblastic differentiation depending on exposure time in rat osteoblastic cells
61. Anabolic or catabolic responses of MC3T3-E1 osteoblastic cells to parathyroid hormone depend on time and duration of treatment
62. On the mechanism of cancellous bone preservation in postmenopausal women with mild primary hyperparathyroidism
63. Bone mineral recovery after parathyroidectomy in patients with primary and renal hyperparathyroidism
64. Vertebral osteopenia: A new indication for surgery in primary hyperparathyroidism
65. Primary hyperparathyroidism and the risk of fracture: A population-based study
66. Primary hyperparathyroidism: Effect of parathyroidectomy on regional bone mineral density in Danish patients: A three-year follow-up study
67. NIH conference: Diagnosis and management of asymptomatic primary hyperparathyroidism: Consensus Development Conference statement
68. Parathyroidectomy in the elderly: Do the benefits outweigh the risks?
69. Correlation of parathyroid scanning and anatomy in 261 unselected patients with sporadic primary hyperparathyroidism
70. Cost utility of routine imaging with Tc-99m-sestamibi in primary hyperparathyroidism before initial surgery
71. Ultrasound evaluation of primary hyperparathyroidism
72. Minimally invasive parathyroidectomy for primary hyperparathyroidism: Decreasing operative time and potential complications while improving cosmetic results
73. Effectiveness and safety of 100 consecutive parathyroidectomies
74. Parathyroidectomy via bilateral cervical exploration: A retrospective review of 866 cases
75. Medical management of primary hyperparathyroidism
76. Developments in the therapeutic applications of bisphosphonates
77. Effect of hormone replacement therapy on bone mineral density in postmenopausal women with mild primary hyperparathyroidism: A randomized, controlled trial
78. Short-term inhibition of parathyroid hormone secretion by a calcium-receptor agonist in patients with primary hyperparathyroidism
79. A calcimimetic agent acutely suppresses parathyroid hormone levels in patients with chronic renal failure: Rapid communication
80. The hyperparathyroidism of chronic renal failure: A disorder of growth
81. The PTH-calcium curve and the set point of calcium in primary and secondary hyperparathyroidism
82. Clonal emergence in uremic parathyroid hyperplasia is not related to MEN1 gene abnormality
83. MEN1 gene mutations in refractory hyperparathyroidism of uremia
84. Pathomorphology of parathyroid autografts
85. Comparison of intact, midregion, and carboxy terminal assays of parathyroid hormone for the diagnosis of bone disease in hemodialyzed patients
86. The spectrum of bone disease in end-stage renal failure - An evolving disorder
87. Relative hypoparathyroidism and a dynamic bone disease
88. Relationship between intact 1-84 parathyroid hormone and bone histomorphometric parameters in dialysis patients without aluminum toxicity
89. Long-term results of total parathyroidectomy without autotransplantation in patients with and without renal failure
90. Suppression of hyperparathyroidism by calcitriol therapy
91. 'Pulse oral' versus intravenous calcitriol therapy in chronic hemodialysis patients: A prospective and randomized study
92. Phosphate binders for control of phosphate retention in chronic renal failure
93. Comparison of treatments for mild secondary hyperparathyroidism in hemodialysis patients
94. Surgical management of secondary hyperparathyroidism in uremia
95. Parathyroid function in long-term renal transplant patients: Importance of pre-transplant PTH concentrations
96. Operative treatment of tertiary hyperparathyroidism: A single-center experience
97. Diagnosis of DiGeorge and Williams syndromes using FISH analysis of peripheral blood smears
98. Transplantation of thymus tissue in complete DiGeorge syndrome
99. Neonatal hypoparathyroidism attributable to homozygous partial deletion of the human glial cell missing gene-B
100. Clinical variation of autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) in a series of 68 patients
101. Mutations in the AIRE gene effects on subcellular location and transactivation function of the autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy protein
102. A novel mutation of the signal peptide of the preproparathyroid hormone gene associated with autosomal recessive familial isolated hypoparathyroidism
103. A familial syndrome of hypocalcemia with hypercalciuria due to mutations in the calcium-sensing receptor
104. Synthetic human parathyroid hormone 1-34 vs calcitriol and calcium in the treatment of hypoparathyroidism
105. Constitutively activated receptors for parathyroid hormone and parathyroid hormone-related peptide in Jansen's metaphyseal chondrodysplasia
106. A homozygous inactivating mutation in the parathyroid hormone/parathyroid hormone-related peptide receptor causing Blomstrand chondrodysplasia
107. Imprinting in Albright's hereditary osteodystrophy
108. Variable and tissue-specific hormone resistance in heterotrimeric Gs protein alpha subunit (Gsalpha) knockout mice is due to tissue-specific imprinting of the Gsalpha gene
109. A GNAS1 imprinting defect in pseudohypoparathyroidism type IB